Availability and Affordability of National Medical Insurance Negotiated Innovative Anticancer Drugs in Changzhou

doi:10.19803/j.1672-8629.2021.11.17

Abstract

Abstract: Objectiv eTo understand the availability and affordability of national medical insurance negotiated innovative anticancer drugs in Changzhou, and to provide evidence for formulating and completing related policy．Methods WHO/HAI standard survey method was adopted to investigate on the availability and affordability of national medical insurance negotiated innovative anticancer drugs in Changzhou, and analyze the factors that affect the results．ResultsThe overall availability of these drugs is really high, with a large number of available varieties, but the access is mainly concentrated in tertiary general hospitals．The affordability of innovative anticancer drugs investigated in this study has been significantly improved after entering medical insurance list, but there is still a large space for improvement．ConclusionThe availability and affordability of these drugs were affected by many factors, including policies, the medical level of hospitals, market requirement, characteristics of tumor epidemiology, generics, etc．In order to further improve the availability and affordability of national medical insurance-negotiated innovative anticancer drugs, it is suggested that it is better to implement and promote the national medical policy, strengthen the management of medical and health institutions, and play further positive role of retail pharmacies．

Key words: Changzhou, innovative anticancer drugs, availability, affordability

CLC Number:

RR73R979.1

JIANG Huiqun, LI Xin, HAN Feng. Availability and Affordability of National Medical Insurance Negotiated Innovative Anticancer Drugs in Changzhou[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1075-1079.

References

[1] Ferlay J, Ervik M, Bray F, et al.Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer[EB/OL].[2021-06-15]. https://giarc.fr/today.
[2] Zhang SL, Ai DD, Zhang R, et al.Study on drug characteristics of NCCN and CSCO clinical practice guidelines for high-prevalence tumors in China[J]. Chinese Journal of New Drugs(中国新药杂志), 2019, 28(20): 2447-2452.
[3] Si L, Xu L, Cheng M, et al.Using strategic price negotiations to contain costs and expand access to medicines in China[J]. BMJ Global Health, 2020, 5(1): e002256.
[4] National Health Commission of the People's Republic of China.Guidelines for the clinical application of innovative anticancer drugs[EB/OL]. (2020-12-30) [2021-06-15]. http://www.nhc.gov.cn/yzygj/s7659/202012/6c00e8559ee54cd29585c7f39e8a23c4.shtml.
[5] Li HY, Yang CP, Jin HT.Research progress in target related toxicity of anti-tumor drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(3): 152-157.
[6] Guan XD, Shi LW.Study on evaluation method for the accessibility of essential medicine in China based on WHO/HAI standardized approach[J]. China Pharmacy(中国药房), 2013 (24): 2212-2215.
[7] Zhou T, Li HC, Zhang JY, et al.The application and its enlightenment of pharmacoeconomic evidence in australian pharmaceutical benefits scheme access[J]. Chinese Health Economics(中国卫生经济), 2018, 37(5): 54-56.
[8] Anum S, Sadia I, Muhammad RS.Availability and affordability of biologic versus non-biologic anticancer medicines: a cross-sectional study in Punjab, Pakistan[J]. BMJ Open, 2018, 8(6): e019015.
[9] Changzhou people's govenment. Changzhou municipal human resources and social security bureau. Notice on the adjustment of minimum wage standard in Changzhou.[EB/OL].(2018-07-20)[2020-01-21].http://www.changzhou.gov.cn/gi_news/419153207791914.
[10] Fang X, Tian MY, Zhang YX, et al.Drugs administration and
individual affordability under different medical insurance entry
11 price: example of anti-tumor targeted medicare drugs[J]. Chinese
12 Journal of Health Policy(中国卫生政策研究), 2016, 9(11): 40-44.
[11] Zhang L, Zhou QY, Zhang XM, et al.Investigation and study on the accessibility of antibiotics in essential medicine list in medical institutions of Nanjing area[J]. China Pharmacy(中国药房), 2020, 31(11): 1281-1287.
[12] Sun KX, Zheng RS, Zhang SW, et al.Report of cancer incidence and mortality in different areas of China, 2015[J]. China Cancer(中国肿瘤), 2019, 28(1): 1-11.
[13] Tang YY, Chen J, Li X.Utilization analysis of the original and generic drugs for hypertension and diabetes in a tertiary public hospital in Jiangsu Province[J]. China Pharmacy(中国药房), 2019, 30(21): 2890-2893.
[14] Wan B, Hu DY, Zhang W, et al.Study on the operation performance of medical insurance funds in Jiangsu under the medical and drug insurance policy reform[J]. Chinese Health Economics(中国卫生经济), 2020, 39(4): 36-39.
[15] Fan CJ, Wang LN, Yang YM.Study on the effect of implementing the drug zero mark-up policy in public hospitals in China[J]. Health Economics Research(卫生经济研究), 2019, 36(2): 53-56.
[16] Chen LL, Xu W, Shang BB, et al.Research on the availability of national negotiated drugs—an empirical analysis based on the purchasing data of public hospitals in Suzhou[J]. Health Economics Research(卫生经济研究), 2020, 37(12): 17-20.